市場監管總局公開徵求意見:6個原料擬納入保健食品原料目錄
格隆匯12月21日丨據央視,近日,市場監管總局組織制修訂了《保健食品原料目錄 營養素補充劑(2022年版)(徵求意見稿)》《允許保健食品聲稱的保健功能目錄 營養素補充劑(2022年版)(徵求意見稿)》和《保健食品原料目錄 蛋白質(徵求意見稿)》,現面向社會公開徵求意見。此次擬納入保健食品原料目錄的原料共6個,包括大豆分離蛋白、乳清蛋白爲功能性保健食品的原料,DHA、酪蛋白磷酸肽+鈣、四氫葉酸鈣和四氫葉酸,氨基葡萄糖鹽爲營養素補充劑的原料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.